ENANTA PHARMACEUTICALS, INC
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $455.6M | $87.1M |
| FY2021 | — | $399.4M | $57.2M |
| FY2022 | — | $321.3M | $44.0M |
| FY2023 | — | $216.7M | $85.4M |
| FY2024 | — | $128.8M | $37.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $455.6M | $87.1M |
| FY2021 | — | $399.4M | $57.2M |
| FY2022 | — | $321.3M | $44.0M |
| FY2023 | — | $216.7M | $85.4M |
| FY2024 | — | $128.8M | $37.2M |